Errata (DOI:10.1016/j.juro.2008.01.043);Risk Stratification for Biochemical Recurrence in Men With Positive Surgical Margins or Extracapsular Disease After Radical Prostatectomy: Results From the SEARCH Database

Journal of Urology

Volumn 179, Issue 5, 2008, Pages 1791-1796

  Jayachandran, Jayakrishnan ^a,b   Bañez, Lionel L ^a,b   Levy, Donna E ^a   Aronson, William J ^c   Terris, Martha K ^f   Presti Jr , Joseph C ^d   Amling, Christopher L ^g   Kane, Christopher J ^e   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g Alabama   (United States)

Author keywords

prostate; prostate specific antigen; prostatectomy; prostatic neoplasms; risk

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; SEMINAL VESICLE; STATISTICAL ANALYSIS;

EID: 41949104559     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2008.09.058     Document Type: Erratum

References (20)

1. Han M., Partin A.W., Pound C.R., Epstein J.I., and Walsh P.C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555
2. Roehl K.A., Han M., Ramos C.G., Antenor J.A.V., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
3. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Schnall M., Tomaszewski J.E., et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154 (1995) 131
4. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
5. Thompson Jr. I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329
6. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572
7. Freedland S.J., Amling C.L., Dorey F., Kane C.J., Presti J.C., Terris M.K., et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 60 (2002) 670
8. Stephenson A.J., Scardino P.T., Eastham J.A., Bianco Jr. F.J., Dotan Z.A., DiBlasio C.J., et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 23 (2005) 7005
9. Harrell Jr. F.E., Califf R.M., Pryor D.B., Lee K.L., and Rosati R.A. Evaluating the yield of medical tests. JAMA 247 (1982) 2543
10. Karakiewicz P.I., Eastham J.A., Graefen M., Cagiannos I., Stricker P.D., Klein E., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 66 (2005) 1245
11. Partin A.W., Piantadosi S., Sanda M.G., Epstein J.I., Marshall F.F., Mohler J.L., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45 (1995) 831
12. Bauer J.J., Connelly R.R., Seterhenn I.A., Deausen J., Srivastava S., McLeod D.G., et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 159 (1998) 929
13. Epstein J.I. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 23 (1996) 651
14. Lowe B.A., and Lieberman S.F. Disease recurrence and progression in untreated pathologic stage t3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 158 (1997) 1452
15. Obek C., Sadek S., Lai S., Civantos F., Rubinowicz D., and Soloway M.S. Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology 54 (1999) 682
16. Khan M.A., Han M., Partin A.W., Epstein J.I., and Walsh P.C. Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology 62 (2003) 86
17. Freedland S.J., Presti J.C., Kane C.J., Aronson W.J., Terris M.K., Dorey F., et al. Do younger men have better biochemical outcomes after radical prostatectomy?. Urology 63 (2004) 518
18. Freedland S.J., Isaacs W.B., Platz E.A., Terris M.K., Aronson W.J., Amling C.L., et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol 23 (2005) 7546
19. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Tomaszewski J.E., and Wein A. A prostate gland volume of more than 75 cm3 predicts for a favorable outcome after radical prostatectomy for localized prostate cancer. Urology 52 (1998) 631
20. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., and Partin A.W. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 176 (2006) 1404